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Background: Poorly controlled hypertension is independently associated with mortality, cardiovascular risk and
disease progression in chronic kidney disease (CKD). In the UK, CKD stage 3 is principally managed in primary care,
including blood pressure (BP) management. Controlling BP is key to improving outcomes in CKD. This study aimed
to investigate associations of BP control in people with CKD stage 3.
Methods: 1,741 patients with CKD 3 recruited from 32 general practices for the Renal Risk in Derby Study
underwent medical history, clinical assessment and biochemistry testing. BP control was assessed by three
standards: National Institute for Health and Clinical Excellence (NICE), National Kidney Foundation Kidney Disease
Outcome Quality Initiative (KDOQI) and Kidney Disease: Improving Global Outcomes (KDIGO) guidelines. Descriptive
statistics were used to compare characteristics of people achieving and not achieving BP control. Univariate and
multivariate logistic regression was used to identify factors associated with BP control.
Results: The prevalence of hypertension was 88%. Among people with hypertension, 829/1426 (58.1%) achieved
NICE BP targets, 512/1426 (35.9%) KDOQI targets and 859/1426 (60.2%) KDIGO targets. Smaller proportions of
people with diabetes and/or albuminuria achieved hypertension targets. 615/1426 (43.1%) were only taking one
antihypertensive agent. On multivariable analysis, BP control (NICE and KDIGO) was negatively associated with age
(NICE odds ratio (OR) 0.27; 95% confidence interval (95% CI) 0.17-0.43) 70–79 compared to <60), diabetes (OR 0.32;
95% CI 0.25-0.43)), and albuminuria (OR 0.56; 95% CI 0.42-0.74)). For the KDOQI target, there was also association
with males (OR 0.76; 95% CI 0.60-0.96)) but not diabetes (target not diabetes specific). Older people were less likely
to achieve systolic targets (NICE target OR 0.17 (95% CI 0.09,0.32) p < 0.001) and more likely to achieve diastolic
targets (OR 2.35 (95% CI 1.11,4.96) p < 0.001) for people >80 compared to < 60).
Conclusions: Suboptimal BP control was common in CKD patients with hypertension in this study, particularly
those at highest risk of adverse outcomes due to diabetes and or albuminuria. This study suggests there is scope
for improving BP control in people with CKD by using more antihypertensive agents in combination while
considering issues of adherence and potential side effects.
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People with chronic kidney disease (CKD) are at in-
creased risk of mortality, cardiovascular disease (CVD)
and less commonly progression to end stage kidney
disease (ESKD) [1,2]. Uncontrolled hypertension, albu-
minuria, and diabetes are independent risk factors for
these adverse outcomes [3-8]. Hypertension is common
in CKD, with estimates of prevalence between 60% and
92% in stage 3 [9-12]. Control of hypertension is argu-
ably the most important intervention for reducing the
increased risk of cardiovascular disease in people with
CKD, and to slow progression to later stages of CKD
[1,11-14]. However, there is evidence that optimum levels
of blood pressure (BP) control are often not achieved
among people with CKD, with consistent achievement
of BP less than 140/90 observed in between 15 and 30%
of patients (with as few as 13% achieving a 130/80
threshold) [15-17].
In the UK (as in many countries) early stages of CKD
are principally managed in primary care. Several na-
tional and international guidelines recommend targets
for optimal BP control in people with CKD but there
are differences between them, including variation of
the targets for those at higher risk of outcome (such
as people with diabetes and albuminuria). In the UK
there are National Institute for Health and Clinical Ex-
cellence (NICE) guidelines on the monitoring and man-
agement of CKD, and, in England, incentivised disease
management targets from the primary care Quality and
Outcomes Framework (QOF) [18,19]. NICE CKD guide-
lines set a BP control at target <140/90 mm Hg for most
people with CKD or <130/80 in people with diabetes
or high levels of albuminuria (ACR > 70 mg/mmol),
while the QOF CKD BP target is ≤140/85 [19,20]. In
the US, the National Kidney Foundation Kidney Dis-
ease Outcome Quality Initiative (NKF KDOQI) guide-
lines set a BP control target at <130/80 for all people
with CKD [21]. The 2012 Kidney Disease: Improving
Global Outcomes (KDIGO) guidelines for the manage-
ment of blood pressure in CKD recommend that both
diabetic and non-diabetic people with non-dialysis de-
pendeant CKD with hypertension but without albumin-
uria should have BP controlled ≤140/90, and people
with significant albuminuria (microalbuminuria or macro-
albuminuria) with or without diabetes should control
BP ≤130/80 [22].
Little is known about CKD-related hypertension con-
trol in primary care, particularly in individuals at higher
risk, such as those with and without diabetes or albu-
minuria. In England QOF data are aggregated at practice
level and do not allow for interpretation at individual
level [23]. This study aimed to evaluate the factors asso-
ciated with blood pressure control in a population of
people with CKD stage 3 in primary care in the UK.Methods
Participants and recruitment
Participants were recruited as part of the Renal Risk in
Derby (RRID) study, a prospective cohort study of people
with CKD stage 3 in a primary care setting. The methods
for the RRID study have been published in detail elsewhere
[24]. In summary, eligible participants were 18 years or
over, met the Kidney Disease Outcomes Quality Initiative
criteria for CKD stage 3 (estimated GFR [eGFR] of be-
tween 30 to 59 ml/min per 1.73 m2 on two or more occa-
sions at least 3 months apart prior to recruitment), were
able to give informed consent, and were able to attend
their general practitioner (GP) surgery for assessments.
People who had previously had a solid organ transplant or
who were terminally ill (expected survival <1 years) were
excluded. The RRID study is conducted by a single neph-
rology department, but participants were recruited directly
from 32 GP surgeries. Eligible patients were invited
to participate via a letter sent by their GP and telephoned
the coordinating centre to schedule a study visit. Study
visits were conducted at participating GP surgeries by
the researchers.
Data collection
First study visits were conducted from August 2008 to
March 2010. Screening and baseline visits were com-
bined due to the large proportion of elderly participants
and the logistical challenges associated with conducting
study visits in multiple primary care centres. Participants
were sent a medical and dietary questionnaire as well as
three urine specimen bottles, and were asked not to eat
cooked meat for at least 12 hours before the assessment.
Urine was collected as three early morning samples. Socio-
economic status (SES) was defined by two methods. First,
using the Indices of Multiple Deprivation score (IMD); a
social deprivation score comprising a composite measure
of seven domains which demonstrates a strong relationship
to health in all geographical locations [25]. Second, self-
reported education status was collected; an important indi-
cator of socioeconomic status in elderly populations [26].
Education status was categorised into eight groups (no for-
mal qualifications, General certificate of Secondary Edu-
cation (GCSE) or equivalent, Advanced level (A level),
National Vocational Qualification (NVQ) 1–3, NVQ 4–5,
first degree, higher degree, patient refused to answer), sub-
sequently grouped into three for the purposes of analysis
(group one: no formal qualifications, group two: GCSE or
equivalent, A level, or NVQ 1–3, group three: first or
higher degree, NVQ 4–5). Self-reported ethnicity informa-
tion was collected, but due to the small number of non-
white participants in this study, it was categorized into
‘White’ and ‘Other’ for the purposes of analysis.
At the assessment, information on questionnaires
was checked, anthropomorphic measurements taken, and
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the three urine specimens were submitted for biochemical
analysis. eGFR was calculated using the modified 4-
variable Modified Diet in Renal Disease equation and
categorised into four groups (>60, 45–59, 30–44, < 30)
[27]. Albuminuria was defined as albumin/creatinine
ratio (ACR) ≥2.5 mg/mmol in men ≥3.5 mg/mmol in
women in at least two of the three urine specimens
(≥3 mg/mmol in all people for the KDIGO guideline ana-
lyses). BMI was calculated from weight in kg divided by
height squared in metres and categorised according to
World Health Organization (WHO) categories under-
weight (<18.5 kg/m2), normal (18.5 – <25 kg/m2), over-
weight (25- < 30 kg/m2), and obese (> = 30 kg/m2) [28].
Central obesity was defined as a waist to hip ratio of ≥0.9
for men or ≥0.8 for women [29]. Diabetes was defined by
having a previous clinical diagnosis in line with WHO
criteria [30]. Previous cardiovascular event was defined
as subject-reported myocardial infarction, stroke, transi-
ent ischemic attack, revascularization, or amputation due
to peripheral vascular disease, or aortic aneurysm. Smok-
ing status was categorized as never smoked, ex-smoker,
and current smoker. Self-reported alcohol consumption
was categorized by units per week as never drinking al-
cohol, drinking within recommended limits (<21 units
for women, <28 units for men), and drinking above rec-
ommended limits. Blood pressure was measured after a
minimum of five minutes rest in the sitting position,
using a validated oscillometric device, recommended by
the British Hypertension Society (Digital Blood Pressure
Monitor Model UA-767, A&D Instruments Ltd, Abingdon,
UK). The same device was used for all readings. BP
was calculated as the mean of three readings that differed
by <10%. Mean arterial pressure (MAP) was calculated as
1/3 the average SBP plus 2/3 the average DBP.
For the purposes of analysis, hypertension was defined as
current antihypertensive medication, but those with a sys-
tolic BP >140 mmHg or diastolic BP >90 mmHg at base-
line who were not on medication were also identified for
descriptive purposes [31]. Target BP threshold was defined
according to three clinical guidelines: the UK NICE guide-
lines BP target (<140/90 or <130/80 in people with dia-
betes and people with ACR > 70 mg/mmol), the US NKF
KDOQI guidelines BP target (<130/80 for all people with
CKD), and the KDIGO guidelines (≤140/90 or 130/80 in
people with albuminuria) [19,21,22].
Participants were asked ‘Were you told that you may
have an issue with your kidneys before you were contacted
to take part in this study?’ Those answering ‘yes’ were de-
fined as being aware of their CKD diagnosis. The study
was approved by the Nottingham Research Ethics Com-
mittee 1. All participants provided written informed con-
sent. The study was included on the National Institute for
Health Research (NIHR) Clinical Research Portfolio (NIHRStudy ID:6632) and was independently audited by QED
Clinical Services in November 2009.
Statistical analyses
In the population of people with hypertension on antihy-
pertensive medication, standard descriptive statistics were
used to compare the characteristics of people achieving
and not achieving BP control by NICE, KDOQI, and
KDIGO BP targets. Univariate and multivariable logistic
regression (adjusting for age, sex, albuminuria, diabetes,
CVD, and eGFR) was used to identify the factors associ-
ated with achievement of the three BP targets. A model
excluding CVD was also constructed to assess the effect
of this variable on outcomes in view of the potential for
CVD to cause lower BP through heart failure. Sensitivity
analyses were conducted in participants whose baseline
eGFR was <60 ml/min/1.73 m2. The logistic regression
analyses were also repeated to examine the associations
of people achieving NICE systolic and diastolic targets
separately. Interaction terms were introduced for gender
by diabetes, age by diabetes, and diabetes by albuminuria
because of the effect modification seen among these vari-
ables in some studies [32]. Chi squared test for trend was
used to examine the degree of BP control by grade of al-
buminuria in people with and without diabetes. For
people on antihypertensive medication or those with ele-
vated BP identified at study registration, multivariable
linear regression was used to investigate the association
between number of antihypertensive medications and
MAP. All odds ratios are presented with 95% confidence
intervals (CIs) and p values <0.05 are considered statisti-
cally significant. IBM SPSS Statistics for Windows ver-
sion 19 was used to analyse the data.
Results
Study population
22% (1741) of approximately 8280 eligible participants
from 32 GP practices invited to be included in the study
agreed to participate (range 8-34% in different GP prac-
tices) and attended baseline assessment. Mean eGFR was
52.5 mL/min/1.73 m2 (SD 10.4). 418 (24%) people had
eGFR ≥ 60 at baseline assessment. 280 (16.1%) had albu-
minuria on two of three ACR measures. 1426 (81.9%)
were taking antihypertensive medication and a further
102 (5.9%) had high BP at study assessment (Table 1).
See Additional file 1: Table S1 for characteristics of people
with and without hypertension.
Antihypertensive treatment
In those taking antihypertensive medication, renin-
angiotensin aldosterone system inhibitors (RAASi) were
the most commonly used (78.8% of patients). Of those on
antihypertensives, 85/98 (86.7%) people who met the NICE
CKD criteria for requiring RAASi (diabetes with any
Table 1 Characteristics of people in the RRID study
Category Total n = 1741 (numbers are n (% of total)unless otherwise stated)
Gender
Male 689 (39.6%)
Female 1052 (60.4%)
Age
<60 128 (7.4%)
60-69 445 (25.6%)
70-79 761 (43.7%)
80+ 407 (23.4%)
Ethnicity
White 1698 (97.5%)
Other 43 (2.5%)
Index of multiple deprivation
Quintile 1 (most deprived) 151 (8.7%)
Quintile 2 432 (24.8%)
Quintile 3 326 (18.7%)
Quintile 4 447 (25.7%)
Quintile 5 (least deprived) 382 (21.9%)
Education status
Group1 (No formal qualifications) 953 (54.7%)
Group 2 (GCSE, Alevel, NVQ 1-3) 469 (26.9%)
Group 3 (1st or higher degree, NVQ 4-5) 317 (18.2%)
eGFR at study entry
Mean (SD) 52.5 (10.4)
> 60 418 (24.0%)
45-59 911 (52.3%)
30-44 386 (22.2%)
<30 26 (1.5%)
Albuminuria
No albuminuria 1456 (83.6%)
Microalbuminuria (≥2.5 mg/mmol M, ≥3.5 mg/mmol F
but <30 mg/mmol)
239 (13.7%)
Macroalbuminuria (≥30 mg/mmol) 41( 2.4%)
Diabetes
Yes 294 (16.9%)
No 1447 (83.1%)
Hypertension
On antihypertensive medication 1426 (81.9%)
BP > 140/90 at study assessment, but not on
antihypertensive medication
102 (5.9%)
No hypertension 213 (12.2%)
Number of antihypertensive
medications
None 315 (18.1%)
1 615 (35.3%)
2 488 (28.0%)
3 or more 323 (18.6%)
Taking RAASi
Yes 1123 (64.5%)
No 618 (35.5%)
History of CVD
Yes 592 (34.0%)
No 1149 (66.0%)
Smoking
Current 81 (4.7%)
Ex-smoker 866 (49.7%)
Never 794 (45.6%)
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Table 1 Characteristics of people in the RRID study (Continued)
Alcohol
No alcohol 711 (40.8%)
Drinking within recommended limits 877 (50.4%)
Drinking above recommended limits 65 (3.7%)
BMI
Normal or underweight 353 (20.3%)
Overweight 738 (42.4%)
Obese 650 (37.3%)
Central obesity
Yes 1480 (85.0%)
No 260 (14.9%)
Total chol:HDL ratio >4.5 306 (17.6%)
Aware of CKD diagnosis
Yes 1026 (58.9%)
No 715 (41.1%)
Abbreviations:
CKD chronic kidney disease.
BP blood pressure.
eGFR estimated Glomerular Filtration Rate.
GCSE General certificate of Secondary Education.
A level Advanced level.
NVQ National Vocational Qualification.
RAASi renin-angiotensin aldosterone system inhibitors.
CVD cardiovascular disease.
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taking them. Among people taking only one agent (n =
615), 425 (69.1%) were taking RAASi, 62 (10.1%) were tak-
ing calcium channel blockers, 61 (9.9%) were taking beta
blockers, and 59 (9.6%) were taking thiazide diuretics.
Mean (±SD) BP for people on antihypertensive agents was
134 (±18) / 72 (±11) mmHg. The NICE BP control target
was achieved in 829/1426 (58.1%), the KDOQI target in
512/1426 (35.9%), and the KDIGO target in 859/1426
(60.2%) (Table 2). BP control varied by diabetes status with
106/276 (38.4%) of people with diabetes achieving the
NICE or KDOQI target (targets are the same in diabetes).
723/1150 (62.9%), 407/1150 (35.3%) and 695/1150 (60.4%)
of people without diabetes achieved the NICE, KDOQI,
and KDIGO targets respectively (Table 2 and Figure 1). In
both people with diabetes and without, optimal control
was less likely in those with albuminuria (Chi-squared test
for trend in non-diabetics = 7.68, p = 0.006, and in dia-
betics = 8.59, p = 0.003) (Figure 1).
Factors associated with suboptimal BP control
On multivariable logistic regression analysis, older patients,
those with diabetes, and those with albuminuria were less
likely to achieve NICE BP targets whereas those with a his-
tory of cardiovascular disease were more likely to achieve
them (Table 3). No difference was observed in these out-
comes when CVD was excluded from the regression
model. Findings for age and albuminuria were similar for
KDOQI and KDIGO targets. The association with diabetes
was not seen with either, but there was an association be-
tween lack of achievement of KDOQI target and male gen-
der. All associations did not vary on sensitivity analysis inthe population with eGFR < 60 at baseline, with the excep-
tion of the loss of the gender association with KDOQI tar-
gets. No association was seen with socioeconomic status,
ethnicity, awareness of CKD diagnosis, alcohol intake,
BMI, central obesity, or taking NSAIDs (data not shown).
There was also no association between number of agents
and achievement of BP control by any of the targets (NICE
OR = 1.12 (95% CI 0.88,1.43), KDOQI OR 1.02 (95% CI
0.80, 1.31), and KDIGO OR 1.05 (95% CI 0.80,1.39)). Mul-
tivariable linear regression controlling for age, gender,
albuminuria, previous CVD, and diabetes identified an as-
sociation between number of antihypertensive drugs taken
and lower MAP. For unit increase in number of anti-
hypertensives, MAP dropped by 2.6 mmHg (95% CI 1.9,3.2,
p < 0.01) (Figure 2). This effect was consistent when people
with previous CVD were excluded from the analysis.
Systolic and diastolic hypertension
Of the 597 people not controlled below the NICE target,
435 (72.9%) had isolated systolic hypertension (≥140), 13
(2.2%) had isolated diastolic hypertension (≥90), and 74
(12.4%) had both systolic and diastolic hypertension.
Table 4 shows the distribution of systolic and diastolic
blood pressure by age and eGFR in the whole study
population. Table 5 shows the variation in systolic and
diastolic hypertension (despite treatment) by age, and dem-
onstrates the predominance of systolic hypertension in
older age groups. Logistic regression analysis of the asso-
ciations of achieving NICE systolic and diastolic targets
separately demonstrated that older people had a lower
odds ratio of achieving systolic targets (OR 0.17 (95% CI
0.09,0.32) p < 0.001 for over 80), and greater odds ratio of
Table 2 Blood pressure control by albuminuria and diabetes status among people on antihypertensive medication
Diabetes, n = 276 No diabetes, n = 1150 Total
n (%)n (column%) unless otherwise stated n (column%) unless otherwise stated
Albuminuria status None
(n = 195)
Micro
albuminuria
(n = 63)
Macro
albuminuria
(n = 18)
Subtotal
diabetes
None
(n = 981)
Micro
albuminuria
(n = 149)
Macro
albuminuria
(n = 20)
Subtotal no
diabetes
n = 1426
Mean BP (SD) Systolic 132 (17) 140 (20) 155 (22) 135 (19) 133 (18) 136 (19) 141 (18) 135 (18) 134 (18)
Diastolic 68 (10) 69 (10) 72 (11) 68 (10) 73 (11) 75 (11) 76 (9) 73 (11) 72 (11)
BP controlled
(NICE target)*
Yes 84 (43.1) 19 (30.2) 3 (16.7) 106 (38.4) 631 (64.3) 86 (57.7) 6 (30.0) 723 (62.9) 829 (58.1)
No 111 (56.9) 44 (69.8) 15 (83.3) 170 (61.8) 350 (35.7) 63 (42.3) 14 (70.0) 425 (37.0) 597 (41.9)
BP controlled
(KDOQI target)**
Yes 84 (43.1) 19 (30.2) 3 (16.7) 106 (38.4) 355 (36.2) 48 (32.2) 4 (20.0) 407 (35.3) 512 (35.9)
No 111 (56.9) 44 (69.8) 15 (83.3) 170 (61.8) 626 (63.8) 101 (67.8) 16 (80.0) 115 (68.9) 914 (64.1)
BP controlled
(KDIGO target)***
Yes 141 (72.3) 21 (33.3) 3 (16.7) 165 (59.8) 639 (65.1) 52 (34.9) 4 (22.2) 695 (60.4) 859 (60.2)
No 54 (27.7) 42 (40.4) 15 (83.3) 111 (40.2) 342 (34.9) 97 (65.1) 14 (77.8) 453 (39.4) 576 (39.8)
Number of
anti-hypertensive
agents
1 79 (40.5) 25 (39.7) 3 (16.7) 107 (38.9) 433 (44.1) 65 (43.6) 8 (40.0) 506 (44.1) 615 (43.1)
2 54 (27.7) 19 (30.2) 5 (27.8) 78 (28.3) 345 (35.2) 61 (40.9) 4 (20.0) 410 (35.7) 488 (34.2)
3 or more 62 (31.8) 19 (30.2) 10 (55.6) 90 (32.6) 203 (20.7) 23 (15.4) 8 (40.0) 232 (20.2) 323 (22.7)
Taking RAASi Yes 173 (88.7) 56 (88.9) 15 (83.3) 243 (88.4) 750 (76.5) 112 (75.2) 17 (85.0) 877 (76.4) 1123 (78.8)
No 22 (11.3) 7 (11.1) 3 (16.7) 32 (11.6) 231 (23.5) 37 (24.8) 3 (15.0) 271 (23.6) 303 (21.2)
* <140/90 or <130/80 in people with diabetes and people with ACR> 70.
** <130/80 for all people with CKD.
*** ≤ 140/90 or 130/80 in people with albuminuria.
Microalbuminuria defined as ACR > =2.5 mg/mmol (men), > = 3.5 mg/mmol (women) in at least two of the three urine specimens.
Macroalbuminuria defined as ACR ≥ 30 mg/mmol.
Abbreviations:
BP blood pressure.
RAASi renin-angiotensin aldosterone system inhibitors.
NICE National Institute for Health and Clinical Excellence.
KDOQI National Kidney Foundation Kidney Disease Outcome Quality Initiative.
ACR albumin/creatinine ratio.
* NICE BP target: <140/90 or <130/80 in people with diabetes and people with ACR>70 
** KDOQI BP target: <130/80 for all people with CKD  
***KDIGO BP target ≤140/90 or 130/80 in people with albuminuria
Figure 1 BP control by diabetes and albuminuria status in 1426 people with CKD 3 and hypertension.
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Table 3 Factors associated with achievement of BP targets in people on antihypertensive medication
Univariate odds
ratios of achieving
NICE BP targets
Multivariable odds
ratios of achieving
NICE BP target ∞
Univariate odds
ratios of achieving
KDOQI BP targets
Multivariable odds
ratios of achieving
KDOQI BP target †
Univariate odds
ratios of achieving
KDIGO BP targets
Multivariable odds
ratios of achieving
KDIGO BP target ∞
OR (95% CI) p OR (95% CI) p OR (95% CI) p OR (95% CI) p OR (95% CI) p OR (95% CI) p
Sex (compared to female) Male 0.91
(0.73,1.12)
0.359 0.88
(0.71,1.10)
0.260 0.80
(0.64,1.00)
0.050 0.76
(0.60,0.96)
0.023 0.75
(0.61,0.93)
0.009 0.93
(0.74,1.18)
0.56
Age (compared to <60 age group) 60-69 0.60
(0.36,1.03)
<0.001 0.43
(0.26,0.71)
<0.001 0.73
(0.46, 1.18)
0.155 0.66
(0.41,1.08)
0.002 0.66
(0.39,1.12)
0.001 0.51
(0.29,0.89)
<0.001
70-79 0.43
(0.26,0.71)
0.27
(0.17,0.43)
0.64
(0.41,1.01)
0.49
(0.31,0.79)
0.52
(0.32,0.87)
0.34
(0.20,0.58)
80+ 0.35
(0.21,0.59)
0.21
(0.13,0.35)
0.60
(0.38, 0.97)
0.43
(0.26,0.72)
0.41
(0.24,0.68)
0.27
(0.15,0.48)
Diabetes (compared to people
without diabetes)
People with
diabetes
0.36
(0.28,0.47)
<0.001 0.32
(0.25,0.43)
<0.001 1.12
(0.86,1.17)
0.410 1.08
(0.81,1.43)
0.601 0.97
(0.74,1.26)
0.796 1.14
(0.85,1.53)
0.38
Albuminuria (compared to no albuminuria) People with
albuminuria
0.54
(0.41,0.72)
<0.001 0.56
(0.42,0.74)
0.001 0.70
(0.52, 0.95)
0.021 0.65
(0.47,0.90)
0.009 0.70
(0.52,0.95)
0.021 0.21
(0.16,0.30)
<0.001
History of CVD (compared to
people with no CVD)
People with
CVD 1.41
(1.13,1.76)
0.002 1.87
(1.49,2.35)
<0.001 1.66
(1.33,2.07)
<0.001 1.89
(1.49,2.39)
<0.001 1.42
(1.14,1.77)
0.002 1.83
(1.43,2.34)
<0.001
eGFR (compared to 45–59) 60+ 1.03
(0.81,1.31)
0.001 0.84
(0.65, 1.09)
0.088 0.78
(0.62,1.00)
0.145 - - 0.97
(0.74,1.28)
0.004 0.83
(0.62,1.11)
0.27
<45 0.66
(0.52, 0.83)
0.77
(0.60, 0.99)
0.92
(0.72, 1.17)
0.66
(0.52,0.85)
0.83
(0.64, 1.09)
∞ Model adjusted for age, sex, albuminuria, diabetes, CVD, and eGFR.
† Model adjusted for age, sex, albuminuria, diabetes, and CVD.
Abbreviations:
BP blood pressure.
RAASi renin-angiotensin aldosterone system inhibitors.
NICE National Institute for Health and Clinical Excellence.
KDOQI National Kidney Foundation Kidney Disease Outcome Quality Initiative.
CVD cardiovascular disease.
eGFR estimated Glomerular Filtration Rate.
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Figure 2 Number of antihypertensive medications and mean arterial BP in people with CKD 3 and hypertension.
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p < 0.001 for over 80) compared to those under 60 years.
Discussion
In this cohort of 1741 people with CKD stage 3, hyper-
tension was common with a prevalence of 88% and BP
control was suboptimal, with 42% not achieving the
NICE BP target, 40% not achieving the KDIGO BP tar-
get, and 64% not achieving the more strict KDOQI BP
target. Presence of diabetes and higher levels of albumin-
uria were associated with a smaller proportion of people
achieving BP control targets. After adjustment for poten-
tial confounding factors, poor BP control was associated
with increasing age and albuminuria for all three BPTable 4 Variation in systolic and diastolic blood pressure by a
<60 6
SBP DBP SBP
mean (SD) mean (SD) mean (SD
mmHg mmHg mmHg
eGFR at baseline >60 n 40
BP 122.1 (15.0) 78.7 (9.8) 131.8 (15.6
45-59.99 n 68
BP 124.2 (15.6) 77.6 (10.1) 130.7 (16.4
30-44.99 n 19
BP 125.5 (22.1) 79.3 (12.73) 133.8 (17.4
<30 n 1
BP 111.3 73.7 137.6 (13.4target groups and with diabetes in the NICE BP target
group. Older age was associated with better diastolic con-
trol and poorer systolic control. Better BP control was as-
sociated with past history of CVD. The majority of patients
were on one or two antihypertensive medications (most
commonly RAASi) and taking a greater number of antihy-
pertensive medications was associated with lower MAP.
The prevalence of hypertension in this cohort is simi-
lar to other studies. In the Chronic Renal Insufficiency
Cohort (CRIC) Study, it was between 82% and 91% in
people with eGFR between 30 and 59 mL/min/1.73 m2
[33]. In the Kidney Early Evaluation Programme (KEEP)
and the National Health and Nutrition Examination
Survey (NHANES), the prevalence of hypertension wasge and eGFR in whole study population
Age
0-69 70-79 80+
DBP SBP DBP SBP DBP
) mean (SD) mean (SD) mean (SD) mean (SD) mean (SD)
mmHg mmHg mmHg mmHg mmHg
148 174 56
) 77.3 (10.0) 136.2 (16.6) 73.9 (9.8) 139.0 (19.3) 75.1 (10.9)
231 412 200
) 74.7 (11.1) 134.3 (16.6) 71.8 (10.6) 138.4 (21.4) 70 (11.1)
63 164 140
) 74.7 (11.8) 135.0 (21.0) 69.0 (10.7) 137.5 (20.7) 69.2 (11.1)
3 11 11
) 68 (16.1) 134.1 (14.4) 72.5 (9.0) 136.1 (19.1) 65.0 (5.49)
Table 5 Variation in systolic and diastolic hypertension by age
Proportion with isolated
systolic hypertension
(SBP >140)
Proportion with isolated
diastolic hypertension
(DBP >90)
Proportion with both systolic
and diastolic hypertension
(SBP >140 and DBP> 90)
Proportion with normal blood
pressure (both SBP < 140
and DBP <90)
Total
Age group <60 7.8% 4.7% 7.0% 80.5% 100%
60-69 20.7% 1.8% 8.1% 69.4% 100%
70-79 32.9% 0.7% 3.7% 62.8% 100%
80+ 39.8% 0.2% 4.2% 55.8% 100%
SBP = systolic blood pressure.
DBP = diastolic blood pressure.
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60 mL/min/1.73 m2 [9,11]. As with previous studies, sys-
tolic hypertension predominated in the uncontrolled group
with hypertension [12]. The findings of poor BP control in
older people, people with diabetes, and people with albu-
minuria are consistent with previous studies [9,31,32]. For
the KDOQI target, we identified similar association with
male gender identified in the Kidney Early Evaluation Pro-
gram (KEEP) cohort, but not the association with obesity
identified in KEEP [9,15]. The predominantly white popu-
lation in this study limited our ability to draw conclusions
about the association between CKD-related hypertension
and ethnicity identified in other studies [9,15,31,34]. The
main concern is that people at greater cardiovascular risk
(older people and people with diabetes and/or albumin-
uria) and people at greater risk of progression (with dia-
betes and albuminuria) were less likely to achieve BP
targets. In the UK in 2010/11, the mean practice-level
achievement of the QOF target for blood pressure control
in CKD patients was 74.9% (standard deviation (SD) 8.2%),
and the median 74.7% [23]. Our study has shown that BP
control may be considerably worse than that when individ-
ual patient data are analysed and more robust targets are
adopted [19,21].
Recent data from the National Diabetes Audit in England
showed that only 36.4% of people with diabetes were
achieving target blood pressure (<140/80 if no co-
morbidity, <130/80 with comorbidity, including CKD) [35].
Our study findings are very similar (38.0% of people with
diabetes achieving BP targets) and add information on BP
control by albuminuria status and in people without dia-
betes (Table 2).
There is evidence that RAAs inhibitors (RAASi) re-
duce progression of CKD in patients with diabetic ne-
phropathy and in those with non-diabetic CKD and
macroalbuminuria, [36,37] although a recent Cochrane
review has not been able to identify sufficient evidence to
determine the effectiveness of RAASi in patients with
stage 1 to 3 CKD who do not have diabetes [38]. In the
UK, NICE guidelines recommend offering RAASi to non-
diabetic people with CKD and hypertension if they have
macroalbuminuria (ACR > =30 mg/mmol), or to people
with diabetic nephropathy who have ACR >2.5 mg/mmolin men or 3/5/mmol in women [19]. RAASi were being
taken by the majority of relevant participants in this study.
Despite not finding a significant association between
numbers of hypertensive agents and achievement of op-
timal BP control, this study demonstrated that a large
proportion of people were only taking one agent. Fur-
thermore, there was an independent association between
the number of antihypertensives and lower MAP, even
when previous CVD was excluded (to remove indication
bias). This suggests there is scope for improving BP control
by the use of more antihypertensive agents in combination.
The lack of association of agent number and optimal con-
trol may be as a result of indication bias, as many older pa-
tients have multiple co-morbidities. In recommendations
to add more agents, risk of side effects, impact on quality
of life, and costs all need to be considered, as well as issues
of medication adherence. The potential for RAASi to pre-
cipitate acute kidney injury, for example, is an important
factor requiring evaluation in this context. BP control and
these related concerns will be important aspects for the
proposed UK national CKD audit in primary care.
Optimal targets for BP control remain the subject of
debate. Furthermore the correct management of isolated
systolic hypertension is uncertain and very low blood
pressure has been associated with poor outcomes, particu-
larly in diabetes [39]. Further research would be valuable in
the context of CKD. In this analysis we applied the two
most widely applied evidence-based guidelines in use at
the time that the study was conducted, NICE and KDOQI,
and added analysis for the KDIGO guidelines in view of
their current relevance.
This study had several strengths, including large num-
bers of people with CKD, being conducted in a primary
care setting, standardisation of blood pressure and other
measures, and the use of three morning urine samples
to assess albuminuria. However, it also has several limi-
tations, including its cross sectional design, which limits
the ability to infer causality (although longitudinal follow
up of this cohort will allow assessment of the effect of
baseline BP on outcome, and of change in BP management
on control). It is possible that people taking a single antihy-
pertensive agent were taking it for other reasons, and that
the observed relationship between CVD and improved BP
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checked this among people with heart failure taking only
one agent and identified only 25 people whose blood pres-
sure was <140/90. We conclude that the risk of bias from
people on single agents for reasons other than hyperten-
sion was therefore low. A further potential limitation is
that a significant proportion of the study population (24%)
were found to have an eGFR ≥60 at baseline, which might
be considered to question their CKD diagnosis. However,
all the participants met the formal definition for CKD prior
to inclusion (including chronicity of low eGFR) and, im-
portantly, were therefore on CKD registers in their respect-
ive GP practices. We therefore included them in the
analyses to improve the generalisability of these findings to
normal practice circumstances. There is also potential that
non response to recruitment could have caused selection
bias, and that the predominantly elderly population could
result in survivor bias. The potential for selection bias
means that caution should be used in application of these
results to general populations with CKD. In addition, we
cannot comment on whether people on antihypertensive
treatment were receiving adequate doses of medication or
adhering. Optimisation of drug dosage might therefore
represent a potential area of improvement not assessed in
this study. This study under-represents ethnic minorities
and the findings should therefore be interpreted with cau-
tion in different ethnic groups. In addition, the study popu-
lation is not representative of the general population due
to the high proportion of older people. However, it in-
cluded a range of general practices from urban and rural
locations, and hence is broadly representative of people
with CKD stage 3 in primary care in the UK. It therefore
highlights the challenges of BP control, and the importance
of measuring urine ACR and using it to guide intervention
in patients with moderate CKD.
Conclusions
Failure to achieve BP targets was common in CKD patients
with hypertension in this study, particularly in those at
highest risk, and systolic hypertension predominated in
those with uncontrolled BP. These findings suggest that
there is scope for improving BP control in CKD stage 3 in
primary care, possibly using more antihypertensive agents
in combination, though there is a need to weigh potential
side effects and costs.
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